Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group

Nucleic Acids Research

Volumn 40, Issue 5, 2012, Pages 2330-2344

  Petrova, Natalya S ^a   Chernikov, Ivan V ^a   Meschaninova, Mariya I ^a   Dovydenko, Iiya S ^a   Venyaminova, Aliya G ^a   Zenkova, Marina A ^a   Vlassov, Valentin V ^a   Chernolovskaya, Elena L ^a  

^a INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CARBON; CHEMICAL COMPOUND; CHOLESTEROL; LITHOCHOLIC ACID; LITHOCHOLIC ACID OLEYLAMIDE; OLEYL ALCOHOL; OLIGOMETHYLENE; PHOSPHONIC ACID DERIVATIVE; PHOSPHORAMIDOUS ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; ATOM; CANCER CELL; CELL TYPE; CHEMICAL BOND; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LIPOPHILICITY; PRIORITY JOURNAL; RNA SYNTHESIS;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHOLESTEROL; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; KINETICS; P-GLYCOPROTEIN; PHENOTYPE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84858396767     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkr1002     Document Type: Article

References (71)

1. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
2. Hammond, S. M., Bernstein, E., Beach, D. and Hannon, G. J. (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature, 404, 293-296.
3. Zamore, P. D., Tuschl, T., Sharp, P. A. and Bartel, D. P. (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 101, 25-33.
4. Chen, S. H. and Zhaori, G. (2010) Potential clinical applications of siRNA technique: benefits and limitations. Eur. J. Clin. Invest., 41, 221-232.
5. Dorsett, Y. and Tuschl, T. (2004) siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov., 3, 318-329.
6. Lares, M. R., Rossi, J. J. and Ouellet, D. L. (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol., 28, 570-579.
7. Jankovic, R., Radulovic, S. and Brankovic-Magic, M. (2009) siRNA and miRNA for the treatment of cancer. J. BUON, 14, S43-S49.
8. Pirollo, K. F. and Chang, E. H. (2008) Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res., 68, 1247-1250.
9. Couto, L. B. and High, K. A. (2010) Viral vector-mediated RNA interference. Curr. Opin. Pharmacol., 10, 534-542.
10. Mowa, M. B., Crowther, C. and Arbuthnot, P. (2010) Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin. Drug Deliv., 7, 1373-1385.
11. Leng, Q., Woodle, M. C., Lu, P. Y. and Mixson, A. J. (2009) Advances in systemic siRNA delivery. Drugs Future, 34, 721.
12. Posadas, I., Guerra, F. J. and Cena, V. (2010) Nonviral vectors for the delivery of small interfering RNAs to the CNS. Nanomedicine, 5, 1219-1236.
13. Shim, M. S. and Kwon, Y. J. (2010) Efficient and targeted delivery of siRNA in vivo. FEBS J., 277, 4814-4827.
14. Bessis, N., GarciaCozar, F. J. and Boissier, M. C. (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther., 11, S10-S17.
15. Check, E. (2002) A tragic setback. Nature, 420, 116-118.
16. Kaiser, J. (2003) Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science, 299, 495.
17. Sinn, P. L., Sauter, S. L. and McCray, P. B. Jr (2005) Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther., 12, 1089-1098.
18. De Souza, A. T., Dai, X., Spencer, A. G., Reppen, T., Menzie, A., Roesch, P. L., He, Y., Caguyong, M. J., Bloomer, S., Herweijer, H. et al. (2006) Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Res., 34, 4486-4494.
19. Song, E., Lee, S. K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P. and Lieberman, J. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med., 9, 347-351.
20. Zender, L. and Kubicka, S. (2007) Suppression of apoptosis in the liver by systemic and local delivery of small-interfering RNAs. Methods Mol. Biol., 361, 217-226.
21. De Paula, D., Bentley, M. V. and Mahato, R. I. (2007) Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA, 13, 431-456.
22. Jeong, J. H., Mok, H., Oh, Y. K. and Park, T. G. (2009) siRNA conjugate delivery systems. Bioconjug. Chem., 20, 5-14.
23. Lv, H., Zhang, S., Wang, B., Cui, S. and Yan, J. (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release, 114, 100-109.
24. Thomas, M., Kularatne, S. A., Qi, L., Kleindl, P., Leamon, C. P., Hansen, M. J. and Low, P. S. (2009) Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. NY Acad. Sci., 1175, 32-39.
25. Lorenz, C., Hadwiger, P., John, M., Vornlocher, H. P. and Unverzagt, C. (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett., 14, 4975-4977.
26. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178.
27. Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M. et al. (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol., 25, 1149-1157.
28. Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H. and Yokota, T. (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther., 16, 734-740.
29. Chu, T. C., Twu, K. Y., Ellington, A. D. and Levy, M. (2006) Aptamer mediated siRNA delivery. Nucleic Acids Res., 34, e73.
30. Hicke, B. J. and Stephens, A. W. (2000) Escort aptamers: a delivery service for diagnosis and therapy. J. Clin. Invest., 106, 923-928.
31. McNamara, J. O. II, Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A. and Giangrande, P. H. (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 24, 1005-1015.
32. Dassie, J. P., Liu, X. Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O. II and Giangrande, P. H. (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol., 27, 839-849.
33. Song, E., Zhu, P., Lee, S. K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P. et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol., 23, 709-717.
34. Xia, C. F., Boado, R. J. and Pardridge, W. M. (2009) Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol. Pharm., 6, 747-751.
35. Chiu, Y. L., Ali, A., Chu, C. Y., Cao, H. and Rana, T. M. (2004) Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol., 11, 1165-1175.
36. Endoh, T. and Ohtsuki, T. (2009) Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev., 61, 704-709.
37. Moschos, S. A., Jones, S. W., Perry, M. M., Williams, A. E., Erjefalt, J. S., Turner, J. J., Barnes, P. J., Sproat, B. S., Gait, M. J. and Lindsay, M. A. (2007) Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem., 18, 1450-1459.
38. Muratovska, A. and Eccles, M. R. (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett., 558, 63-68.
39. MacKellar, C., Graham, D., Will, D. W., Burgess, S. and Brown, T. (1992) Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. Nucleic Acids Res., 20, 3411-3417.
40. Manoharan, M., Kesavan, V. and Rajeev, K. G. (2005), US Patent 20050107325 A1.
41. Rump, E. T., de Vrueh, R. L., Sliedregt, L. A., Biessen, E. A., van Berkel, T. J. and Bijsterbosch, M. K. (1998) Preparation of conjugates of oligodeoxynucleotides and lipid structures and their interaction with low-density lipoprotein. Bioconjugate Chem., 9, 341-349.
42. Sergeeva, Z. A., Lokhov, S. G. and Ven'yaminova, A. G. (1996) Oligo(20-O-methylribonucleotides) and their derivatives. II. Synthesis and properties of oligo(2'-O-methylribonucleotides) modified with N-(2-hydroxyethyl)phenazinium and steroid groups at the 5'-terminus. Bioorgan. Khim., 22, 916-922.
43. Bellon, L. (2001) Oligoribonucleotides with 2'-O-(tert- butyldimethylsilyl) groups. Curr. Protoc. Nucleic Acid Chem., doi: 10. 1002/0471142700. nc0306s01.
44. Proudnikov, D. and Mirzabekov, A. (1996) Chemical methods of DNA and RNA fluorescent labeling. Nucleic Acids Res., 24, 4535-4542.
45. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. and Mitchell, J. B. (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res., 47, 943-946.
46. Logashenko, E. B., Vladimirova, A. V., Repkova, M. N., Venyaminova, A. G., Chernolovskaya, E. L. and Vlassov, V. V. (2004) Silencing of MDR 1 gene in cancer cells by siRNA. Nucleosides Nucleotides Nucleic Acids., 23, 861-866.
47. Volkov, A. A., Kruglova, N. S., Meschaninova, M. I., Venyaminova, A. G., Zenkova, M. A., Vlassov, V. V. and Chernolovskaya, E. L. (2009) Selective protection of nucleasesensitive sites in siRNA prolongs silencing effect. Oligonucleotides., 19, 191-202.
48. Chiu, Y. L. and Rana, T. M. (2003) siRNA function in RNAi: a 115 chemical modification analysis. RNA, 9, 1034-1048.
49. de Fougerolles, A., Vornlocher, H. P., Maraganore, J. and Lieberman, J. (2003) Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov., 6, 443-453.
50. Richert, N. D., Aldwin, L., Nitecki, D., Gottesman, M. M. and Pastan, I. (1988) Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry, 27, 7607-7613.
51. Anthony, V. and Skach, W. R. (2002) Molecular mechanism of P-glycoprotein assembly into cellular membranes. Curr. Protein Pept. Sci., 3, 485-501.
52. Juliano, R. L. and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455, 152-162.
53. Gottesman, M. M. and Pastan, I. (1989) Clinical trials of agents that reverse multidrug-resistance. J. Clin. Oncol., 7, 409-411.
54. Kruglova, N. S., Meshchaninova, M. I., Ven'iaminova, A. G., Zenkova, M. A., Vlasov, V. V. and Chernolovskaia, E. L. (2010) Cholesterol-modified anti-MDR1 small interfering RNA: uptake and biological activity. Mol. Biol., 44, 284-293.
55. Krieg, A. M., Tonkinson, J., Matson, S., Zhao, Q., Saxon, M., Zhang, L. M., Bhanja, U., Yakubov, L. and Stein, C. A. (1993) Modification of antisense phosphodiester oligodeoxynucleotides by a 50-cholesteryl moiety increases cellular association and improves efficacy. PNAS, 90, 1048-1052.
56. Manoharan, M., Tivel, K. L. and Cook, P. D. (1995) Lipidic nucleic acids. Tetrahedron Lett., 36, 3651-3654.
57. Stein, C. A., Pal, R., DeVico, A. L., Hoke, G., Mumbauer, S., Kinstler, O., Sarngadharan, M. G. and Letsinger, R. L. (1991) Mode of action of 5-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro. Biochemistry., 30, 2439-2444.
58. Venyaminova, A. G., Sergeyeva, Z. A. and Bashirova, V. Z. (1991) HPhosphonates of hydroxysterols as new key compounds for the synthesis of sterol derivatives of mono-, oligonucleotides and their analogues. Bioorgan. Khim., 17, 1294-1296.
59. Brown, M. S. and Goldstein, J. L. (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell, 89, 331-340.
60. Plosch, T., Kosters, A., Groen, A. K. and Kuipers, F. (2005) The ABC of hepatic and intestinal cholesterol transport. Handb. Exp. Pharmacol., 465-482.
61. Burnett, J. R. and Barrett, P. H. (2002) Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. Crit. Rev. Clin. Lab. Sci., 39, 89-137.
62. Deckelbaum, R. J., Shipley, G. G. and Small, D. M. (1977) Structure and interactions of lipids in human plasma low density lipoproteins. J. Biol. Chem., 252, 744-754.
63. Havekes, L. M., De Wit, E. C. M. and Princen, H. M. G. (1987) Cellular free cholesterol in Hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity. Biochem. J., 247, 739-746.
64. Kambouris, A. M., Roach, P. D., Calvert, G. D. and Nestel, P. J. (1990) Retroendocytosis of high density lipoproteins by the human hepatoma cell line, HepG2. Arteriosclerosis, 10, 582-590.
65. Marsche, G., Frank, S., Raynes, J. G., Kozarsky, K. F., Sattler, W. and Malle, E. (2007) The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. Biochem. J., 402, 117-124.
66. Feinberg, E. H. and Hunter, C. P. (2003) Transport of dsRNA into cells by the transmembrane protein SID-1. Science, 301, 1545-1547.
67. Dominska, M. and Dykxhoorn, D. M. (2010) Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci., 123, 1183-1189.
68. Turner, J. J., Arzumanov, A. A. and Gait, M. J. (2005) Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucleic Acids Res., 33, 27-42.
69. Turner, J. J., Fabani, M., Arzumanov, A. A., Ivanova, G. and Gait, M. J. (2006) Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell delivery. Biochim. Biophys. Acta, 1758, 290-300.
70. Turner, J. J., Ivanova, G. D., Verbeure, B., Williams, D., Arzumanov, A. A., Abes, S., Lebleu, B. and Gait, M. J. (2005) Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res., 33, 6837-6849.
71. Farhood, H., Serbina, N. and Huang, L. (1995) The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta., 1235, 289-295.